Chemiquest Research India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 21 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 Cr
- Revenue Growth 1.33%
- Profit Growth 0.21%
- Ebitda 186.69%
- Net Worth 9.16%
- Total Assets -4.66%
About Chemiquest Research India
Chemiquest Research India Private Limited (CRIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 21 October 2003 and has a history of 21 years and four months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.00 Cr.
Samir Shah, Pravin Shah, and Yatin Shah serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24100MH2003PTC142790
- Company No.
142790
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Oct 2003
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Chemiquest Research India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Samir Shah  | Director | 21-Oct-2003 | Current |
| Pravin Shah | Director | 21-Oct-2003 | Current |
| Yatin Shah | Director | 21-Oct-2003 | Current |
Financial Performance of Chemiquest Research India.
Chemiquest Research India Private Limited, for the financial year ended 2019, experienced modest growth in revenue, with a 1.33% increase. The company also saw a slight improvement in profitability, with a 0.21% increase in profit. The company's net worth moved up by a moderate rise of 9.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chemiquest Research India?
In 2019, Chemiquest Research India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹20.00 M
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 2.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Nov 2013 | Axis Bank Limited | ₹2.00 Cr | Open |
How Many Employees Work at Chemiquest Research India?
Unlock and access historical data on people associated with Chemiquest Research India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chemiquest Research India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chemiquest Research India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.